This study investigates the safety and effectiveness of combining two investigational medications, teclistamab and mezigdomide, for individuals with relapsed or refractory multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. When these cells become cancerous, they can cause damage to bones, kidneys, and the immune system.
Participants in the study will receive both teclistamab and mezigdomide. The study will monitor participants for any side effects and determine how well the combination of these investigational medications works in treating multiple myeloma. Participants will undergo various tests and evaluations to assess their response to the treatment.
- Who can participate: Individuals aged 18 and older with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy are eligible. Participants must have measurable disease and meet specific health criteria. Women of childbearing potential must agree to use effective contraception.
- Study details: Participants will receive teclistamab and mezigdomide as part of the study procedures. They will be monitored for safety and treatment response. A placebo is not used in this study.